Negative in Ames, in vitro micronucleus and in vivo mouse bone marrow micronucleus assays
“Ziftomenib was not mutagenic in an in vitro bacterial reverse mutation assay and was not genotoxic in an in vitro micronucleus assay or in an in vivo mouse bone marrow micronucleus assay.”
Not conducted (not warranted for the proposed indication)
“The FDA concurs. Carcinogenicity studies were not warranted for the proposed indication.”
✓ VerifiedFDA multi-discipline review, p. 109Source ↗
Reproductive & developmental
EFD: cleft palate at high dose and skeletal malformations (ribs, skull, vertebrae) at all doses
“External malformations were elevated in the high-dose group fetuses and composed of cleft palates. Skeletal malformations were observed in all test article dose groups, notably in the ribs, skull, and vertebra.”
✓ VerifiedFDA multi-discipline review, p. 38Source ↗
Safety pharmacology
hERG IC50 1.61 µM, Cav1.2 IC50 2.8 µM; lower blood pressure and longer PR interval in dogs
“The IC50 values for hERG and hCavl.2 inhibition were 1.61 and 2.8 μM, respectively. Dose-dependent lower blood pressure and longer PR intervals were seen after single doses of 40, 120, and 200 mg/kg/day in dogs”
✓ VerifiedFDA multi-discipline review, p. 36Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative